Browse News

Found 162 articles

• Mammotome Launches the HydroMARK™ Plus Breast Biopsy Site Marker, an Innovation for Tissue Marker Displacement

  8/21/2023

  Mammotome announced the launch of an innovative new HydroMARK™ Plus Breast Biopsy Site Marker designed to enhance ultrasound visibility, improve ease of locating, and mitigate displacement during surgical procedures.

• New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

  6/8/2023

  A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.

• Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

  6/5/2023

  Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.

• Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting

  6/2/2023

  Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced an oral presentation of Phase 1 DF1001 Monotherapy Dose Escalation Results scheduled on Sunday June 4, from 11:45 - 11:57 a.m.

• Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team to help Manage its Growing Clinical Pipeline

  6/1/2023

  Dragonfly Therapeutics, Inc., announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.

• Bruker Advances NMR Magnet Portfolio, Innovates in Industrial Solutions

  4/17/2023

  At the Experimental Nuclear Magnetic Resonance Conference (ENC 2023), Bruker announces innovations for NMR spectroscopy in life science, pharma, and cleantech research to enable discoveries in functional structural biology, drug discovery, and battery research.

• Dragonfly Therapeutics Announces the Publication of Preclinical Data Supporting DF6002, its Extended Half-life IL-12 Cytokine, as A Promising Treatment for Cancer

  4/17/2023

  Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced the April 13th publication of preclinical data in Cell Press's Med supporting DF6002 as a promising treatment option for cancer patients.

• Harbour BioMed Reports Full Year 2022 Financial Results

  4/3/2023

  Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2022.

• Carterra Expands Best-in-Class Franchise With the Launch of the LSAXT High-Throughput SPR Biosensor at SLAS 2023

  2/27/2023

  Carterra Expands Best-in-Class Franchise With the Launch of the LSA XT High-Throughput SPR Biosensor at SLAS 2023.

• 

  Another IL-12 Candidate Bites the Dust as AstraZeneca Shifts Focus

  2/9/2023

  AstraZeneca announced it is making significant cuts from its pipeline in an attempt to realign its priorities and recover from waning COVID-19 drug sales. 

• UK approval of DragonflyTM Respiratory diagnostic that identifies five most common viral infections

  2/8/2023

  Rapid molecular point-of-care diagnostic system reliably detects SARS-CoV-2, Flu A, Flu B, RSV and Human Rhinovirus

• 

  Dragonfly Welcomes BMS-Dropped IL-12 Asset Back into the Fold (Updated)

  2/7/2023

  Bristol Myers Squibb has returned the rights for interleukin-12 immunotherapy program​​​​​​​ DF6002 back to its original owner, Dragonfly Therapeutics, the companies announced Monday. 

• Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program

  2/6/2023

  Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe.

• Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

  2/2/2023

  Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.

• Dr. Joseph E. Eid, Who Led Merck's Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D

  2/1/2023

  Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Joseph E. Eid, M.D., has joined the Company as President of Research and Development.

• Adimab Provides 2022 Update on Clinical Pipeline

  1/11/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation.

• Adimab Provides Year-End Update on 2022 Partnership Activities

  1/10/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

• ProtonDx and Katalyst Announce Strategic Partnership to Distribute Dragonfly™ In Vitro Diagnostic

  1/9/2023

  Exclusive rights to distribute CE-IVD marked Dragonfly diagnostic system in key client segments. Dragonfly System able to detect five common respiratory pathogens at once.

• Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

  1/6/2023

  Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.

• Microbot Medical Announces MedTech Industry Veteran Joe Mullings will Moderate the Next ‘Access-Ability Live by MBOT’ Webinar

  1/6/2023

  Microbot Medical Inc., the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, announced that Joe Mullings, a renowned and successful leader in the medtech space, will moderate the next Access-Ability Live by MBOT webinar.